Compare Crispr Therapeutics AG (CRSP) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Symbotic Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Symbotic Inc trades at $42.63 (market cap $5.46B). The key difference: Crispr Therapeutics AG and Symbotic Inc are close in size by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Symbotic Inc for 23 Days on average.
| CRSP | SYM | |
|---|---|---|
Market Cap | $4.88B | $5.46B |
Volume | 2,861,747 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $73.97 | $87.30 |
52-Week Low | $44.34 | $38.22 |
Typical Hold Time | 77 Days | 23 Days |
Enterprise Value | $3.30B | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
SYM trades at $42.06, down 2.89% today, with bearish technical signals from moving averages. The company shows mixed fundamentals with negative net income of -$16.94M in 2025 but improving revenue growth to $2.6B projected for 2026. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst sentiment remains positive with 61% buy ratings and a $60.33 consensus target, representing 43% upside potential from current levels.
SYM presents a growth story with strong revenue expansion and massive $22.5B backlog, but faces profitability challenges and customer concentration risk with Walmart accounting for 85% of revenue. The stock trades at attractive valuation multiples with P/E of 1,051.5 and P/S of 2.01, though high EV/EBITDA of 74.05 reflects growth expectations. Near-term catalysts include Q3 2026 earnings and execution on the substantial order backlog.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
